P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

• J. Senapati,
• J. Ishizawa,
• H. A. Abbas,
• S. Loghavi,
• G. Borthakur,
• G. C. Issa,
• S. I. Dara,
• R. Pourebrahim,
• N. Daver,
• E. J. Jabbour,
• S. M. Kornblau,
• N. Pemmaraju,
• G. Garcia-Manero,
• F. Ravandi,
• M. Muftuoglu,
• J. Khoury,
• C. DiNardo,
• M. Andreeff

Affiliations

J. Senapati

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

J. Ishizawa

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

H. A. Abbas

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

S. Loghavi

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

G. Borthakur

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

G. C. Issa

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

S. I. Dara

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

R. Pourebrahim

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

N. Daver

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

E. J. Jabbour

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

S. M. Kornblau

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

N. Pemmaraju

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

G. Garcia-Manero

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

F. Ravandi

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

M. Muftuoglu

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

J. Khoury

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

C. DiNardo

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America

M. Andreeff

1 Leukemia, MD Anderson Cancer Center, Houston, United States of America